


Serial No.: 09/943,382

Atty. Dkt. No. 072121-0139  
16325.002



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul A. Renhowe *et al.*

Title: HETEROCYCLIC DERIVATIVES OF  
QUINOLINONE BENZIMIDAZOLES

Appl. No.: 09/943,382

Filing Date: August 30, 2001

Examiner: Rita J. Desai

Art Unit: 1625

**RECEIVED**

DEC 08 2003

TECH CENTER 1600/2900

**AMENDMENT AND SUBMISSION FOR  
REQUEST FOR CONTINUED EXAMINATION**

MAIL STOP RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Examiner:

This amendment is in reply to a final Office Action mailed on June 2, 2003, and accompanies a Request for Continued Examination (RCE) that is filed herewith. The shortened three-month statutory period for response to the Office Action expired on September 2, 2003. With the accompanying petition for extension of time and the requisite fee, this response is timely filed.

Applicants believe that no fees in addition to those enclosed for the petition for extension of time and the filing of the RCE are required. However, should any additional fee(s) be due, the Commissioner is hereby authorized, under 37 CFR §§ 1.16-1.17, to charge any fee(s) that may be due to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing,

the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350. Duplicates of page 1 and the signature page are enclosed for such purpose.

The amendments presented below are in compliance with the revised amendment format permitted in the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office dated February 10, 2003, and published at 1267 OG 106 on February 25, 2003. Thus, the provisions of 37 CFR § 1.121(a), (b), (c) and (d) are waived for amendments made in this application to the claims.

***Amendments to the Claims*** begin on page 3 of this paper.

***Listing of the Claims*** begins on page 3 of this paper.

***Remarks*** begin on page 11 of this paper